Several other risk factors for relapse in patients with AIH have been reported, such as a shorter duration of inactive disease prior to treatment withdrawal, increased serum ALT and IgG levels at drug withdrawal, and delayed biochemical remission.[46], [47], [48] These findings suggest that the incidence of relapse is associated with sustained inflammatory and immune responses. Here, GPT is linked to autoimmune hepatitis.